Claire Tucker, Head of Sales and Marketing

Richmond Pharmacology's (RPL's) highly successful business team has recently undergone a re-organisation to enhance the outstanding service we provide to our valued clients.Claire Tucker, Head of Sales and Marketing, commented:‘Our improved structure includes dedicated business Account Managers, specifically allocated to a particular client and able to guide them through the initial stages of introduction and study specific contract negotiation. These Account Managers continue to be at hand throughout as an additional point of contact until the study has reached its completion. As usual, our proficient Clinical Project Managers will co-ordinate the smooth day-to-day running of the study and will continue to work on a one to one basis with client teams. I am delighted with the new structure and the impact this is already having on our clients.’This framework has been introduced to ensure even better communication from initial contact through to close out, maintaining RPL's supportive and personal approach.Providing additional support for Phase II is our dedicated Phase II Department, see more on our patient studies page.

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event